TP53 and myeloid neoplasm: In a recent study evaluating 66 melphalan-treated cases, the biological characteristics were found to be consistent with the usual pCT group of myeloid malignancies presenting with a complex karyotype (48.5%) and TP53 mutations (67.2%), with the latter being the sole mutation in over one third of cases.